What drugs does Hikma make?

Hikma has 464 FDA-approved drugs including IMMPHENTIV, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, TYZAVAN.

What therapeutic areas does Hikma focus on?

Hikma focuses primarily on Infectious Disease and Oncology and 1 other therapeutic areas.

Data updated: Jun 28, 2026

Hikma

Generics

Infectious Disease Oncology Cardiovascular

Hikma is a generic drug manufacturer focused on Infectious Disease, Oncology, Cardiovascular. Key products include IMMPHENTIV.

1947

Since

464

Drugs

Trials

New Drugs (2yr)

Modality:

19 Small Molecules

Hikma's Key Drugs

Hikma's core commercial portfolio centers on IMMPHENTIV, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, TYZAVAN, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.

IMMPHENTIV

Pain

Cough

alpha-1 adrenergic receptor Approved 2012

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Hay Fever

Septicemia

Multiple Myeloma

Opioid Overdose

opioid receptor Approved 2021

Hikma's Recent FDA Approvals

Hikma secured 8 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

EPINEPHRINE NDA

2026-03-30

epinephrine

1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

ROCURONIUM BROMIDE NDA

2025-10-24

rocuronium bromide

Routine tracheal intubation

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

ROCURONIUM BROMIDE NDA

2025-06-09

rocuronium bromide

Routine tracheal intubation

Skin and Skin Structure Infections

Hikma's Therapeutic Areas

Hikma's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Oncology, across 0 biologic and 19 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 24%

26 drugs

Oncology 21%

23 drugs Phase 2: 1 Phase 1: 1

Cardiovascular 21%

23 drugs

Neurology 18%

19 drugs Phase 3: 1

Dermatology 16%

18 drugs

Hikma's Top Competitors

Hikma's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma

Oncology, Infectious Disease, Neurology, Dermatology

Baxter specialty

Infectious Disease, Cardiovascular, Oncology, Dermatology

GE HEALTHCARE specialty

Neurology, Cardiovascular, Infectious Disease, Oncology

FOUGERA PHARMS other

Dermatology, Oncology, Cardiovascular, Infectious Disease

Merck big-pharma

Oncology, Infectious Disease, Cardiovascular